Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Humacyte (HUMA – Research Report) today and set a price target of $15.00. The company’s shares closed last Friday at $4.70.
Jackson covers the Healthcare sector, focusing on stocks such as NeoGenomics, Humacyte, and Tenon Medical, Inc.. According to TipRanks, Jackson has an average return of -19.6% and a 31.52% success rate on recommended stocks.
Humacyte has an analyst consensus of Strong Buy, with a price target consensus of $8.00.
Based on Humacyte’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $25.11 million. In comparison, last year the company had a GAAP net loss of $3.72 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humacyte (HUMA) Company Description:
Alpha Healthcare Acquisition Corp is a blank check company.
Read More on HUMA:
